ArticleOnco2022

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma.

Fatih M Uckun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.